Latest & greatest articles for dabigatran

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dabigatran or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dabigatran and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dabigatran

61. Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial (PubMed)

Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required.The current analysis was undertaken to compare the periprocedural bleeding risk of patients in the Randomized (...) Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial treated with dabigatran and warfarin. Bleeding rates were evaluated from 7 days before until 30 days after invasive procedures, considering only the first procedure for each patient. A total of 4591 patients underwent at least 1 invasive procedure: 24.7% of patients received dabigatran 110 mg, 25.4% received dabigatran 150 mg, and 25.9% received warfarin, P=0.34. Procedures included: pacemaker/defibrillator insertion (10.3%), dental procedures

Full Text available with Trip Pro

2012 EvidenceUpdates

62. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. (PubMed)

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. To analyse clinical outcomes with new oral anticoagulants for prophylaxis against venous thromboembolism after total hip or knee replacement.Systematic review, meta-analysis, and indirect treatment comparisons.Medline and CENTRAL (up to April 2011), clinical trials registers, conference proceedings, and websites (...) of regulatory agencies.Randomised controlled trials of rivaroxaban, dabigatran, or apixaban compared with enoxaparin for prophylaxis against venous thromboembolism after total hip or knee replacement. Two investigators independently extracted data. Relative risks of symptomatic venous thromboembolism, clinically relevant bleeding, deaths, and a net clinical endpoint (composite of symptomatic venous thromboembolism, major bleeding, and death) were estimated using a random effect meta-analysis. RevMan and ITC

Full Text available with Trip Pro

2012 BMJ

63. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 NHS Economic Evaluation Database.

64. Dabigatran for Stroke Prevention in Atrial Fibrillation: A Review of the Evidence on Safety

Dabigatran for Stroke Prevention in Atrial Fibrillation: A Review of the Evidence on Safety Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed (...) to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Dabigatran for Stroke Prevention in Atrial Fibrillation: A Review of the Evidence on Safety DATE: 06 March 2012 CONTEXT AND POLICY ISSUES Atrial fibrillation (AF) is a type of cardiac dysrhythmia that is estimated to affect between

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

65. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses Pink J, Lane S, Pirmohamed M, Hughes DA Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of dabigatran etexilate and warfarin in patients with non-valvular atrial fibrillation and a moderate-to-high risk of stroke. Dabigatran 110mg

2012 NHS Economic Evaluation Database.

66. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J (...) , Bradley-Kennedy C, Plumb JM Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the cost-effectiveness of dabigatran etexilate versus warfarin (trial data) or usual care (warfarin, aspirin, or no treatment) for stroke

2012 NHS Economic Evaluation Database.

67. Dabigatran (Pradaxa?): risk of serious haemorrhage

Dabigatran (Pradaxa?): risk of serious haemorrhage Dabigatran (Pradaxa▼): risk of serious haemorrhage - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Dabigatran (Pradaxa▼): risk of serious haemorrhage Contraindications clarified and reminder to monitor renal function. Published 11 December 2014 From: Therapeutic area: , Contents Article date: July 2012 Dabigatran (Pradaxa▼) is a reversible inhibitor of free thrombin, fibrin-bound thrombin, and thrombin-induced platelet (...) aggregation. It is licensed for primary prevention of venous thromboembolic events in adults who have had elective total hip replacement surgery or total knee replacement surgery (at 220 mg/day), and for prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and one or more cardiovascular risk factors (at 300 mg/day). Haemorrhage is a common adverse reaction with dabigatran. A review of world-wide data on the risk of bleeding with dabigatran, including results from

2012 MHRA Drug Safety Update

68. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Kansal AR, Sharma M (...) , Bradley-Kennedy C, Clemens A, Monz BU, Peng S, Roskell N, Sorensen SV Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of dabigatran versus rivaroxaban as anticoagulation therapies for prevention

2012 NHS Economic Evaluation Database.

69. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain

Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain Gonzalez-Juanatey JR, Alvarez-Sabin J, Lobos JM, Martinez-Rubio A, Reverter JC, Oyaguez I, Gonzalez-Rojas N, Becerra V Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of dabigatran compared with warfarin and other prescribing patterns for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in Spain. The authors concluded that dabigatran cost effective

2012 NHS Economic Evaluation Database.

70. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C CRD summary (...) All-cause deaths were equivalent for each treatment, but apixaban and dabigatran 110mg seemed to prevent more strokes, with least risk, for patients with non-valvular atrial fibrillation; dabigatran 150mg seemed better for patients at high risk of embolism. The review was generally poorly reported. The indirect comparisons and potential for confounding mean that the conclusions may not be reliable. Authors' objectives To compare the efficacy and safety of dabigatran, rivaroxaban, and apixaban

2012 DARE.

71. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249) Overview | Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation | Guidance | NICE Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation Technology appraisal guidance [TA249] Published date: 15 March 2012 Share Guidance on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults

2012 National Institute for Health and Clinical Excellence - Technology Appraisals

72. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

73. What role can dabigatran,rivaroxaban and apixaban play in the future?

What role can dabigatran,rivaroxaban and apixaban play in the future? Vol 19. DTB: Vol 19, No 3. May - July 2011 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DTB: Vol 19, No 3. May - July 2011 DTB: Vol 19, No 3. May - July 2011 Content tools Share it What role can dabigatran, rivaroxaban and apixaban play in the future? Dabigatran, rivaroxaban and apixaban have shown to be non inferior to warfarin. However these drugs might

2011 Drug and Therapeutics Bulletin of Navarre (Spain)

74. Acutely injured patients on dabigatran. (PubMed)

Acutely injured patients on dabigatran. 22111735 2011 12 09 2015 11 19 1533-4406 365 21 2011 Nov 24 The New England journal of medicine N. Engl. J. Med. Acutely injured patients on dabigatran. 2039-40 10.1056/NEJMc1111095 Cotton Bryan A BA McCarthy James J JJ Holcomb John B JB eng Letter United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Benzimidazoles 11P2JDE17B beta-Alanine I0VM4M70GC Dabigatran AIM IM N Engl J Med. 2012 Mar 1;366(9):863; author reply 864 22375993 Anticoagulants (...) adverse effects Benzimidazoles adverse effects Dabigatran Hemorrhage chemically induced Humans Thrombelastography Whole Blood Coagulation Time Wounds and Injuries complications beta-Alanine adverse effects analogs & derivatives 2011 11 25 6 0 2011 11 25 6 0 2011 12 14 6 0 ppublish 22111735 10.1056/NEJMc1111095

2011 NEJM

75. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation

Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Shah SV, Gage BF Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of treatments to prevent stroke in patients with atrial fibrillation. The authors concluded that dabigatran 150mg twice daily was cost-effective for populations at high risk of haemorrhage or stroke, unless the control of the international normalised ratio with warfarin was excellent. The methods were good and reported adequately, with the results reported in full. Given the scope of the analysis

Full Text available with Trip Pro

2011 NHS Economic Evaluation Database.

76. Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery

Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery (...) Ringerike T, Hamidi V, Hagen G, Reikvam A, Klemp M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ringerike T, Hamidi V, Hagen G, Reikvam A, Klemp M. Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery. Oslo: Norwegian Knowledge Centre

2011 Health Technology Assessment (HTA) Database.

77. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of low- or high-dose dabigatran, compared with warfarin, for the prevention of ischaemic stroke in patients aged 65 years or older, with non-valvular atrial fibrillation and risk factors for stroke. The authors concluded that dabigatran, particularly at a high

Full Text available with Trip Pro

2011 NHS Economic Evaluation Database.

78. [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery]

[Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L (...) . Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor. [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe Tecnico Breve No 41. 2011 Authors' objectives To assess the available evidence on the efficacy, safety and other issues related with coverage policies on the use of dabigatran and rivaroxaban as thrombophylaxis after a major orthopedic surgery. Authors

2011 Health Technology Assessment (HTA) Database.

79. Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison

Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

80. Dabigatran etexilate - Prevention of stroke and systemic embolism in patients with atrial fibrillation

Dabigatran etexilate - Prevention of stroke and systemic embolism in patients with atrial fibrillation CEDAC M Notice of © 2011 C New I Recomm The Can listed for meeting • P n r e a o • P Reason 1. In on stroke daily with d comp dabig obse 2. The d when Backgro This sub Canada fibrillation through d indication Meeting – Mar CEDAC Fina ADTH Indication: mendation: adian Exper the prevent one of the fo Patients in w normalized r regular INR t education. P anticoagulati or Patients who for the Rec (...) e large open e or systemi (1.11%) com dabigatran 1 pared with ad gatran 150 m rved in centr daily cost of n monitoring ound: mission for d indication of n, in whom a direct inhibit n. The Healt rch 23, 2011; l Recommend CEDA [Pradax – : Preventio rt Drug Advis ion of stroke ollowing crite whom warfar ratio (INR) co testing, dosa Patients who ion managem o have a hist commendati n-label rando ic embolism mpared with 10 mg twice djusted dose mg twice dail res that faile dabigatran ( costs

2011 Canadian Agency for Drugs and Technologies in Health - Common Drug Review